Top Qs
Timeline
Chat
Perspective
Simtuzumab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads